Knight Therapeutics Inc. GUD.TO
Set alert
As of Oct 30, 4:00 PM ET
- YTD
- +86.28%
- 1 year
- +94.31%
- Open
- 11.34
- Prev close
- 11.40
- Mkt cap
- 1.11B
- Vol
- 15.72K
- Avg vol
- 82.56K
- EPS
- 0.15
- P/E
- 75.13
- Div yield
- 0.00%
More statistics
- Low
- 11.25
- High
- 11.41
- Forward P/E
- 43.38
- Beta
- -0.01
- Short ratio
- 15.66
- Inst. own
- 19.04%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.38
- 200-d avg
- 8.50
- 1y target
- 11.65
2Y chart
Signals (102)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 29, 2026 | 2 days ago |
| RSI: Overbought | Oct 19, 2026 | 1 week ago |
| MACD: Buy Signal | Sep 2, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| RSI: Overbought | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 8, 2026 | 4 months ago |
| RSI: Overbought | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | May 21, 2026 | 5 months ago |
| MACD: Buy Signal | May 7, 2026 | 5 months ago |
| RSI: Overbought | May 7, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 16, 2026 | 6 months ago |
| RSI: Overbought | Mar 23, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 20, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 13, 2026 | 8 months ago |
| RSI: Overbought | Feb 13, 2026 | 8 months ago |
| SMA: Bullish | Feb 12, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 16, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 14, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 13, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 2, 2026 | 10 months ago |
| SMA: Bearish | Jan 2, 2026 | 10 months ago |
| SMA: Bullish | Dec 31, 2025 | 10 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
| SMA: Bullish | Dec 10, 2025 | 10 months ago |
| SMA: Bullish | Dec 10, 2025 | 10 months ago |
| SMA: Bearish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 25, 2025 | 11 months ago |
| SMA: Bullish | Nov 6, 2025 | 11 months ago |
| SMA: Bullish | Nov 6, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 20, 2025 | 1 year ago |
| RSI: Oversold | Oct 14, 2025 | 1 year ago |
| SMA: Bearish | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Oct 2, 2025 | 1 year ago |
| RSI: Oversold | Oct 2, 2025 | 1 year ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 30, 2025 | 1 year ago |
| RSI: Oversold | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 17, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 22, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 21, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 20, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 15, 2025 | 1 year ago |
| RSI: Overbought | Aug 11, 2025 | 1 year ago |
| RSI: Overbought | Aug 7, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| SMA: Bearish | Jun 19, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 19, 2025 | 1 year ago |
| SMA: Bullish | Jun 5, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 4, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| SMA: Bearish | May 8, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 25, 2025 | 1 year ago |
| SMA: Bullish | Apr 24, 2025 | 1 year ago |
| SMA: Bearish | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 27, 2025 | 1 year ago |
| RSI: Overbought | Mar 19, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| RSI: Overbought | Mar 11, 2025 | 1 year ago |
| SMA: Bearish | Mar 7, 2025 | 1 year ago |
| SMA: Bullish | Mar 4, 2025 | 1 year ago |
| SMA: Bearish | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 11, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 3, 2025 | 1 year ago |
| RSI: Overbought | Jan 28, 2025 | 1 year ago |
| RSI: Overbought | Jan 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 23, 2024 | 1 year ago |
Key statistics
- Market cap
- 1.11B
- Enterprise value
- 1.03B
- Trailing P/E
- 75.20
- Forward P/E
- 43.38
- PEG ratio
- 0.00
- Price / sales
- 2.02
- Price / book
- 1.39
- EPS (TTM)
- 0.15
- Beta
- -0.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 2.72%
- Revenue (TTM)
- 547.31M
- Revenue growth
- 34.30%
- Free cash flow
- 63.38M
- Total cash
- 121.17M
- Total debt
- 34.28M
- Return on equity
- 1.91%
- Shares outstanding
- 98.23M
- Short % of float
- 0.00%
- 50-day average
- 10.38
- 200-day average
- 8.50
Analyst view
Consensus: strong buy
- Target (low)
- 10.80
- Target (mean)
- 11.65
- Target (high)
- 14.00
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.01.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 6, 2024 | Raymond James | main | Outperform | Outperform |
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- knighttx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on GUD.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bosano (Leopoldo Agustin) | Senior Officer of Issuer | Exercise of rights | Mar 22, 2026 | 19,476 |
| Emblem (Susan Caroline) | Senior Officer of Issuer | Acquisition or disposition under a purchase/ownership plan | Sep 14, 2026 | 46,311 |
| Gale (James) | Director of Issuer | Exercise of options | Apr 12, 2026 | 52,997 |
| Goodman (Jonathan Ross) | Director of Issuer | Acquisition or disposition under a purchase/ownership plan | Sep 14, 2026 | 1,036,111 |
| Khouri, Amal | Senior Officer of Issuer | Acquisition or disposition under a purchase/ownership plan | Sep 14, 2026 | 200,810 |
| Lande (Robert Nathaniel) | Director of Issuer | Acquisition or disposition in the public market | May 13, 2026 | 223,178 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artisan Partners Funds Inc.-Artisan International Explorer Fund | 1.41% | 1,390,451 | 15.68M | Jun 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT. | 0.86% | 841,363 | 9.49M | Jul 30, 2026 |
| DFA INVESTMENT TRUST CO-The Canadian Small Company Series | 0.49% | 484,400 | 5.46M | Jul 30, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.38% | 372,491 | 4.20M | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional International Small Cap Value ETF | 0.31% | 304,699 | 3.44M | Jul 30, 2026 |
| Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund | 0.25% | 246,614 | 2.78M | Jul 30, 2026 |